



THE BRITISH JOURNAL OF PSYCHIATRY

October 1995

Vol. 167

Editorials

Clozapine, eating disorders and substance abuse.
Obstacles to innovation in a peripheral hospital.

M. Launer

431

Biological psychiatry and reductionism.
Empirical findings and philosophy. *H. Karlsson*
and *M. Kamppinen*

434

Review Article

Supportive psychotherapy. The search for
positive meanings. *J. Holmes*

439

Peer review of Supportive psychotherapy. *M. F.*
Robertson and P. Tyrer

446

Papers

Nine suicide pacts. A clinical study of a
consecutive series, 1974–93. *M. Brown, E.*
King and B. Barraclough

448

Behaviour symptoms among severely and
profoundly mentally retarded patients. A 16–
18 year follow-up study. *A. H. Reid and B. R.*
Ballinger

452

Social deprivation and psychiatric admission
rates among different diagnostic groups. *J.*
Harrison, S. Barrow and F. Creed

456

First admission incidence study of mania, 1975–
1981. *I. Daly, M. Webb and M. Kaliszer*

463

Gender-specific changes since 1900 in the
season-of-birth effect in schizophrenia. *J. M.*
Eagles, D. Hunter and J. R. Geddes

469

Immigrant families coping with schizophrenia.

Behavioural family intervention v. case
management with a low-income Spanish-
speaking population. *C. Telles, M. Karno, J.*
Mintz, G. Paz, M. Arias, D. Tucker and S. Lopez

473

Antipsychotic drug-induced dysphoria. *D. J.*
King, M. Burke and R. A. Lucas

480

Cyproheptadine treatment in neuroleptic-induced
akathisia. *D. Weiss, D. Aizenberg, H. Hermesh,*
Z. Zemishlany, H. Munitz, M. Radwan and A.
Weizman

483

Long-term follow-up after a drug trial for panic
disorder. *H. Katschnig, M. Amering, J. M.*
Stolk, G. L. Klerman, J. C. Ballenger, A. Briggs,
R. Buller, G. Cassano, M. Garvey, Sir Martin
Roth and C. Solyom

487

Incorporating psychological debriefing tech-
niques within a brief group psychotherapy
programme for the treatment of post-traumatic
stress disorder. *W. Busuttill, G. J. Turnbull, L.*
A. Neal, J. Rollins, A. G. West, N. Blanch and
R. Herepath

495

Neuraesthesia revisited: ICD–10 and DSM–III–R
psychiatric syndromes in chronic fatigue patients
and comparison subjects. *A. Farmer, I. Jones,*
J. Hillier, M. Llewelyn, L. Borysiewicz and A.
Smith

503

Recurrent brief episodes with psychotic features
in adolescence: periodic psychosis of puberty
revisited. *K. Abe and M. Ohta*

507


continued p. ii

Published by The Royal College of Psychiatrists

ISSN 0007–1250

Now you can lift depression with the body in mind

Site-specific 'Cipramil' addresses four key dimensions of antidepressant therapy:



Cipramil[▼]
citalopram

Specifically treating depression

Abbreviated Prescribing Information

Presentation: 'Cipramil' tablets, PL 0458/0058, each containing 20mg of citalopram as the hydrobromide. 28 (OP) 20mg tablets £21.28.

Indications: Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. **Dosage:** Adults: 20mg a day. Depending upon individual patient response, this may be increased in 20mg increments to a maximum of 60mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. **Elderly:** 20mg a day increasing to a maximum of 40mg dependent upon individual patient response. **Children:** Not recommended. Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery. History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors; leave a seven day gap before starting MAO inhibitor treatment. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and

tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. Alcohol is not advised. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd, Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. 'Cipramil' is a trademark. © 1995 Lundbeck Ltd.

Date of preparation: May 1995

References

1. Hyttel J, XXII Nordiske Psykiater-Kongres, Reykjavik, 11 August, 1988: 11-21.
2. Eison AS et al, Psychopharmacology Bull 1990; 26 (3): 311-315.
3. Rosenberg C et al, Int Clin Psychopharmacol 1994; 9 (Suppl 1): 41-48.
4. Shaw DM et al, Br J Psychiatry 1986; 149: 515-517.
5. Bech P and Cialdella P, Int Clin Psychopharmacol 1992; 6 (Suppl 5): 45-54.
6. Sindrup SH et al, Ther Drug Monit 1993; 15: 11-17.
7. Van Harten J, Clin Pharmacokinet 1993; 24 (3): 203-220.

Lundbeck

Research for a better life

The British Journal of Psychiatry

October 1995

Volume 167

No. 4

Editor Greg Wilkinson *Liverpool*

Senior Associate Editor

Alan Kerr *Newcastle upon Tyne*

Associate Editors

Sidney Crown *London*

Julian Leff *London*

Sir Martin Roth *Cambridge*

Sir Michael Rutter *London*

Peter Tyrer *London*

Editorial Advisers

Herschel Prins *Leicester*

Sir John Wood *Sheffield*

Assistant Editors

Mohammed Abou-Saleh *Al-Ain*

Louis Appleby *Manchester*

German Berrios *Cambridge*

Alistair Burns *Manchester*

Patricia Casey *Dublin*

John Cookson *London*

David Cottrell *Leeds*

Nigel Eastman *London*

Tom Fahy *London*

Anne Farmer *Cardiff*

Nicol Ferrier *Newcastle upon Tyne*

William Fraser *Cardiff*

Richard Harrington *Manchester*

Sheila Hollins *London*

Jeremy Holmes *Barnstaple*

Alexander Kellam *Cardiff*

Peter Kennedy *York*

Alan Lee *Nottingham*

Shôn Lewis *Manchester*

Robin McCreadie *Dumfries*

Ian McKeith *Newcastle upon Tyne*

Roy McClelland *Belfast*

Stuart Montgomery *London*

David Owens *Leeds*

Ian Pullen *Edinburgh*

Rosalind Ramsay *London*

Henry Rollin *London*

Jan Scott *Newcastle upon Tyne*

Andrew Sims *Leeds*

Jeanette Smith *Bristol*

George Stein *London*

David Tait *Perth*

Corresponding Editors

Sidney Bloch *Australia*

Patrice Boyer *France*

J.M. Caldas de Almeida *Portugal*

Andrew Cheng *Taiwan*

Andrei Cristian *Romania*

E. L. Edelstein *Israel*

Václav Filip *Czech Republic*

Heinz Katschnig *Austria*

Kenneth Kendler *USA*

Toshi Kitamura *Japan*

Arthur Kleinman *USA*

F. Lieh Mak *Hong Kong*

Jair Mari *Brazil*

Harold Merskey *Canada*

Paul Mullen *Australia*

Ahmed Okasha *Egypt*

Volodymer Poltavetz *Ukraine*

Michele Tansella *Italy*

Toma Tomov *Bulgaria*

John Tsiantis *Greece*

J. L. Vázquez-Barquero *Spain*

Richard Warner *USA*

Statistical Adviser

Pak Sham *London*

Staff

Publications Manager

Dave Jago

Scientific Editor

Lesley Bennun

Deputy Scientific Editor

Aliki Buhayer

Assistant Scientific Editor

Dinah Alam

Editorial Assistants

Judy Ashworth

Julia Burnside

Marketing Assistant

Dominic Bentham

Past Editors

Eliot Slater 1961–72 Edward H. Hare 1973–77 John L. Crammer 1978–83 Hugh L. Freeman 1984–93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963

Published by the Royal College of Psychiatrists

Contents continued from front cover

The post-concussional state: neurophysiological aspects. <i>M. R. Watson, G. W. Fenton, R. J. McClelland, J. Lumsden, M. Headley and W. H. Rutherford</i>	514	sufferers. <i>C. Ballard, C. Bannister, C. Graham, F. Oyebode and G. Wilcock</i>	537
Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine. <i>J. D. C. Mellers, N. P. Quinn and M. A. Ron</i>	522	Validation of a French version of an informant-based questionnaire as a screening test for Alzheimer's disease. <i>S. Law and C. Wolfson</i>	541
Excess mortality among elderly psychiatric in-patients with organic mental disorder. <i>W. Rössler, W. Hever, B. Färkenheuer and W. Löffler</i>	527	Prevalence of psychiatric morbidity among remand prisoners in Scotland. <i>M. Davidson, M. S. Humphreys, E. C. Johnstone and D. G. Cunningham Owens</i>	545
Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. <i>J. Norrman, A. J. Brookes, C. Yates and D. St Clair</i>	533		
Associations of psychotic symptoms in dementia			

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. All communications, including manuscripts for publication, should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG.

Full instructions to authors are given at the beginning of the January and July issues.

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1995 (12 issues post free) are as follows:

Europe (& UK): institutions £148, individuals £130
US: institutions \$295, individuals \$210
Elsewhere: institutions £175, individuals £138
Full airmail is £36/US\$64 extra.
Single copies of the Journal are £14, \$25 (post free).

Payment should be made out to the British Journal of Psychiatry.

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

© 1995 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

Columns

Correspondence	549
A hundred years ago	554
Books reconsidered. <i>Psychiatry in Dissent</i> (Anthony Clare). <i>L. Appleby</i>	555
Book reviews	557
<i>American Journal of Psychiatry</i> (contents)	563

Back issues

Back issues published before 1995 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$295. Second class postage paid at Rahway, NJ. Postmaster send address corrections to the *British Journal of Psychiatry*, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

©™ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences - Permanence of Paper for Printed Library Materials. ANSI Z39.48-1984.

Typeset by Dobbie Typesetting Ltd, Tavistock, and Henry Ling Ltd.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

ESSENTIAL PSYCHIATRY BOOKS FROM



New in Paperback

FORENSIC PSYCHIATRY

Clinical, Legal and Ethical Issues

Edited by

John Gunn MB FRCPsych

Professor of Forensic Psychiatry, Institute of Psychiatry, London, UK

Pamela J Taylor MB BS MRCP FRCPsych

Professor of Special Hospital Psychiatry, Broadmoor Hospital and the Institute of Psychiatry, London; formerly Head of Medical Services, Special Hospitals Service Authority, London, UK

'Forensic psychiatry is a welcome textbook for workers in the field. It is a practical guide. . . I recommend the book to psychiatrists, psychologists, lawyers and sociologists.'

The Lancet, January 1994

This authoritative and comprehensive textbook of Forensic Psychiatry is a source book for a wide range of issues concerned with the interaction between law and psychiatry. Multidisciplinary in authorship, it is orientated towards practical issues, especially the treatment of mentally disordered offenders.

March 1995 234 × 156mm 1050 pages 12 line illustrations PAPERBACK 0 7506 2317 9 £65

New Edition

STUDENT PSYCHIATRY TODAY

A Comprehensive Textbook

Second Edition

Robert I Cohen MB BS LRCP MRCS DRCOG

MRCPsych Dip Crim

Consultant Psychiatrist and Medical Director, St Andrews at Harrow, Harrow-on-the Hill, UK

Jerome J Hart MRCPsych

Consultant Psychiatrist, North Herts NHS Trust, Lister Hospital, Stevenage, Herts, UK

New for the second edition:

- Several chapters extensively revised and updated to encompass modern approaches to diagnosis, brought about by the ICD-10 classification system
- Recent developments in genetic research, brain imaging techniques and drug treatments included
- Chapters dealing with community and liaison psychiatry considerably expanded
- New sections devoted to important topical issues, such as clinical audit and psychiatric emergencies

A highly regarded text of outstanding value to undergraduates and junior doctors.

May 1995 234 × 156mm 448 pages PAPERBACK 0 7506 1586 9 £19.99

Order Form

Books may be ordered from your usual bookseller, or in case of difficulty from: Sophie Foster, Butterworth-Heinemann, Linacre House, Jordan Hill, Oxford OX2 8DP UK. Orders can be placed direct by telephoning our Customer Services Department on (01933) 414000.

Please supply the following titles:

Qty	Title	ISBN	Price £
_____	Forensic Psychiatry	0 7506 2317 9	£65.00
_____	Student Psychiatry Today	0 7506 1586 9	£19.99

Please add £2.50 for UK and European surface post delivery (add £6.00 for air mail delivery)

In Europe add VAT at local rate

NB. ZERO RATE FOR UK AND EIRE

TOTAL:

(Remittance enclosed £_____ Cheques should be made payable to **Reed Book Services Ltd.**

Please debit my credit card as follows:

Access/Mastercard Barclaycard/Visa American Express Diners Club

Credit Card No: _____ Expiry Date: _____

NAME (PLEASE PRINT): _____

ADDRESS: _____

SIGNATURE: _____

DATE: _____

Butterworth-Heinemann Limited - Registered Office: Michelin House, 81 Fulham Road, London SW3 6RB. Registered in England: 194771.

VAT number GB: 340 2429 92

M501MMXA01

Butterworth-Heinemann, Linacre House, Jordan Hill, Oxford OX2 8DP, UK

Tel: (01865) 310366 Fax: (01865) 310898



NORTHERN REGION MENTAL HEALTH PROGRAMME

Two new positions are offered due to the expansion of the Mental Health Programme, which serves the Northern Region population of 127,000 based around the town of Launceston.

Tasmania is the smallest state in Australia and is known for its attractive lifestyle, with a large rural sector, mountains, sea, river and bushwalking opportunities and the region has ready access to all of these. The climate is probably the most similar to Britain of anywhere in Australia, but considerably warmer. Launceston is an historic town with all the usual urban facilities including shops, schools, theatre and a University campus.

The Mental Health Programme is based in the Launceston General Hospital, which, with 385 beds, has a full range of general medical and surgical facilities. The Mental Health Programme Manager is also a practising psychiatrist. The Programme includes acute ward and long-stay residence, rehabilitation service, child and adolescent service and newly established community mental health team. The Programme is part of the Tasmanian Registrar Training Scheme in Psychiatry and has links with the University of Tasmania for teaching medical, nursing and social work students.

PSYCHIATRIST

(Position Number – G1640-040)

The Psychiatrist will join the existing team of four consultants who work with in-patients and out-patients/community patients in the various programme settings. The mix of duties is negotiable according to special interests of the applicant but an interest in community psychiatry would be an advantage.

CHILD AND ADOLESCENT PSYCHIATRIST

(Position Number – G1620-003)

A Child Psychiatrist is sought for the new position and will take over leadership of the "Oakrise" Child and Adolescent Service on retirement of the present Medical Director. The present establishment of four clinical staff is currently increasing to six. The service uses a range of individual and family approaches and offers consultation to various other local agencies.

CONDITIONS OF SERVICE

Employment is offered on a contract basis and an attractive package of salary and additional benefits will be negotiated for suitable applicants. All packages include annual, study, sabbatical and long service leave and rights of private practice. Relocation expenses are paid. (Note that private practice is much more highly developed by most hospital specialists in Australia than in Britain due to the Medicare funding available to patients and may provide significant additional satisfaction – e.g. through devoting time to a sub-speciality interest – and income).

Full position descriptions, confidential discussion or further details of the Mental Health Services are available by contacting:

Dr Rosemary Schneider
Programme Manager Mental Health
Launceston General Hospital
LAUNCESTON TASMANIA
AUSTRALIA 7250
Telephone: (003) 327746
Facsimile: (003) 327773



The Government of Tasmania is an equal opportunity employer. For all positions applications are invited from persons regardless of sex, marital status, ethnic origin, or disability.



THE CHALLENGE OF THE
DEMENTIAS
LANCET CONFERENCE

Edinburgh, UK
April 25 & 26 1996

Chairman Robin Eastwood (Can)

Participating Speakers

K.Ritchie (Fra), C.Brayne (UK), S.Henderson (Aus),
I.Skoog (Swe), R.Bland (Can), J.Jolles (NL), J.Copeland (UK),
A.Roses (USA), P. St George-Hyslop (Can),
L.Amaducci (It), G.Schellenberg (USA), P.Whitehouse (USA),
R.Tallis (UK), J.Morris (USA), M.Storandt (USA),
R.Levy (UK), B.Dickens (Can), A.Burns (UK),
G.A.Broe (Aus), M.Rossor (UK), V.Hachinski (Can)

The 1996 Lancet conference is aimed at a multispecialty response to 'The Challenge of the Dementias: Towards a Better Understanding of Cognitive Impairment'.

The four main themes are epidemiology; genetics and biomarkers; neuroimaging, neuropsychology, and neuropathology; and social aspects, including caring and ethical issues.

Each session will have a plenary lecture followed by 3 or more shorter presentations. Discussion will form a major part of the programme and posters will be on display throughout.

A document detailing research priorities will appear in The Lancet and there will be an Investigator Award for best poster presentation.

- The conference will be held at the Edinburgh International Conference Centre, which is in the heart of the city, and only 20 minutes from the international airport.
- Hotel Accommodation can be booked through our agents, Scot World Travel. A comprehensive booking form will be sent to all registered delegates.
- A Scottish Gala Evening will be held at Hopetoun House, Scotland's finest stately home, on April 25, 1996. Entertainment will be provided by a harpist and a piper, and a banquet will be served in the Adam Ballroom. Coach transport is included in the ticket price of £50 + VAT at the local rate of 17.5%. Total payable £58.75.

PROGRAMME

DAY 1 (Thursday April 25, 1996)

07.30 - 09.00 Registration
09.00 - 09.05 Introduction: R.Horton, Editor of The Lancet
09.05 - 09.15 Chairman's Introduction: R.Eastwood
09.15 - 10.45 (A) EPIDEMIOLOGY
Chair: J.Copeland (UK)
Plenary Speaker: K.Ritchie (Fra)
Speakers: C.Brayne (UK); S.Henderson (Aus); I.Skoog (Swe)
R.Bland (Can); J.Jolles (Neth)
10.45-11.30 Coffee and opportunity to view poster panels
11.30-12.45 Panel discussion with speakers listed at (A) above and also P.Whitehouse (USA); M.Storandt (USA); A.Roses (US)
12.45-14.15 Lunch and opportunity to view poster panels
14.15-15.45 (B) GENETICS AND BIOMARKERS
Chair: P.Whitehouse (USA)
Plenary Speaker: A.Roses (USA)
Speakers: P.St George-Hyslop (Can); L.Amaducci (It); G.Schellenberg (USA)
15.45-16.15 Tea and opportunity to view poster panels
16.15-17.30 Panel discussion with speakers listed at (B) above and also R.Levy (UK); S.Henderson (Aus); G.A.Broe (Aus)

DAY 2 (Friday April 26, 1996)

09.00-09.15 Introduction: R.Tallis (UK)
09.15-10.45 (C) NEUROIMAGING, NEUROPSYCHOLOGY, AND NEUROPATHOLOGY
Chair: V.Hachinski (Can)
Plenary Speaker: J.Morris (USA)
Speakers: G.A.Broe (Aus); M.Storandt (USA); M.Rossor (UK)
10.45-11.30 Coffee and opportunity to view poster panels
11.30-12.45 Panel discussion with speakers listed at (C) above and also K.Ritchie (Fra); P.St George-Hyslop (Can); A.Burns (UK)
12.45-13.45 Lunch and opportunity to view poster panels
13.45-15.00 (D) SOCIAL ASPECTS: DIAGNOSIS, TREATMENT, LEGAL AND ETHICAL ISSUES
Chair: R.Eastwood (Can)
Plenary Speaker: R.Levy (UK)
Speakers: A.Burns (UK); P.Whitehouse (USA); B.Dickens (Ca)
15.00-15.30 Tea and opportunity to view poster panels
15.30-16.30 Panel discussion with speakers listed at (D) above and also A.Roses (USA); C.Brayne (UK); J.Morris (USA)
16.30-17.00 Presentation of Investigator Award followed by closing address and depart

Details correct at the time of going to press

Registration Fee

For delegates registering before January 19, 1996, the fee is £350 + Value Added Tax (VAT) at the local rate of 17.5%. Total payable £411.25.
For delegates registering after January 19, 1996, the fee is £400 + Value Added Tax (VAT) at the local rate of 17.5%. Total payable £470.
Registration fees include access to all sessions, lunch, refreshments, and a copy of the delegate programme and abstract book.

Written notification of cancellations received before April 4, 1996, will qualify for a 90% refund; those received between April 4 and April 18 will qualify for a 40% refund. Cancellations after this date are liable for the full registration fee.

REGISTRATION FORM

Please send completed forms to:
Phillipa Orme, The Lancet Dementia Conference Secretariat, Elsevier Science Publishers Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK.
Tel: +44 (0) 1865 843 691 Fax: +44 (0) 1865 843 958
Please photocopy this form for multiple registrations.
Complete in block capitals.

Family Name _____
First Name _____ Title (Prof, Dr, Mr, Ms) _____
Job Title _____
Organisation _____
Address _____
Post/Zip Code _____ Country _____
Telephone _____ Telefax _____

- Please register me as a delegate at the preferential rate* of £350 + VAT @17.5%. Total payable £411.25
 Please register me as a late delegate at £400 + VAT @ 17.5%. Total payable £470
 Please book _____ place(s) at the Gala Evening on April 25 at £50 + VAT @ 17.5%. Total payable £58.75
*Preferential rate applies to delegates who register by January 19, 1996

TOTAL COST EXCLUDING ACCOMMODATION £

A booking form for accommodation will be sent to all registered delegates giving det for a range of hotels in Edinburgh, including price, classification, and distance from the conference centre.

Payment

I enclose a cheque/banker's draft in £ Sterling made payable to Elsevier Science Ltd Please charge my Access/ Visa/ AmEx/ Mastercard/ Eurocard (delete as applicable)

Card No.

Expiry date _____ Today's date _____ Signature _____

Name and address of cardholder if different from the above _____

I understand and agree to abide by the terms and conditions set out in the registration information

Signature _____

Date _____

—INTRODUCING—

THE WORLD'S FIRST

S · N · R · I

SEROTONIN NORADRENALINE REUPTAKE INHIBITOR



Space photography provided courtesy of National Aeronautics and Space Administration (NASA).

The result of original Wyeth research and development, Efexor (venlafaxine) is the first of a new class of antidepressants, the SNRIs.

Efexor is a major step forward in selective reuptake inhibition and increases the availability of both of the key neurotransmitters involved in depression.¹ This is in line with current thinking on the pathophysiology of depression, which stresses the importance of interactions between serotonin and noradrenaline.²

Extensive clinical trials of Efexor in over 2,500 depressed patients have confirmed the success of this approach. Efexor has been shown to be at least as effective and better tolerated than standard tricyclic and related antidepressants such as dothiepin, imipramine and trazodone.³

Efexor has also been shown to compare favourably with the SSRI fluoxetine in inpatient¹ and outpatient studies.¹ Furthermore, Efexor demonstrates a significant dose response curve which allows flexibility of treatment in a wide range of patients.¹

For many depressed patients, the world's first SNRI could make a world of difference.

EFEXOR[®]
VENLAFAXINE

A NEW CLASS OF ANTIDEPRESSANT

PRESCRIBING INFORMATION: PRESENTATION: Tablets containing 37.5mg or 75mg venlafaxine (as hydrochloride). USE: Treatment of depressive illness. DOSAGE: Usually 75mg/day (37.5mg bd) with food, increasing to 150mg/day (75mg bd) if necessary. In more severely depressed patients, 150mg/day (75mg bd) increasing every 2 or 3 days in up to 75mg/day increments to maximum 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually. Elderly: use normal adult dose. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. CONTRA-INDICATIONS: Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. PRECAUTIONS: Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their

ability to do so is impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their Doctor should an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. INTERACTIONS: MAOIs: do not use Efexor in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor before starting a MAOI. SIDE-EFFECTS: Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety,

impotence, abnormality of accommodation, vasodilation, vomiting, tremor, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise in blood pressure, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol. BASIC NHS PRICE: 37.5mg tablet (PL 0011/0199) – Calendar pack of 56 tablets: £23.97, 75mg tablet (PL 0011/0201) – Calendar pack of 56 tablets: £39.97. LEGAL CATEGORY: POM. Further information is available upon request. PRODUCT LICENCE HOLDER: Wyeth Laboratories (John Wyeth & Brother Limited), Taplow, Maidenhead, Berkshire SL6 0PH. REFERENCES: 1. Clerc GE *et al.* *Int Clin Psychopharmacol* 1994; 9: 139-142. 2. Kalus O, Asnis GH, van Praag HM, *Psychiatric Annals* 1989; 19: 348-353. 3. Data on file, Medical Affairs Department, Wyeth-Ayerst International Inc. Date of Preparation: December 1994. Code Z770380/1294. *EFEXOR is a registered trademark.